- Home
- PAMT vs VNDA Comparison
PAMT vs VNDA Comparison
Compare PAMT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAMT
- VNDA
- Stock Information
- Founded
- PAMT 1980
- VNDA 2002
- Country
- PAMT United States
- VNDA United States
- Employees
- PAMT N/A
- VNDA N/A
- Industry
- PAMT Trucking Freight/Courier Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- PAMT Industrials
- VNDA Health Care
- Exchange
- PAMT Nasdaq
- VNDA Nasdaq
- Market Cap
- PAMT 223.5M
- VNDA 249.4M
- IPO Year
- PAMT 1985
- VNDA 2006
- Fundamental
- Price
- PAMT $10.85
- VNDA $5.54
- Analyst Decision
- PAMT Hold
- VNDA Strong Buy
- Analyst Count
- PAMT 1
- VNDA 2
- Target Price
- PAMT $13.00
- VNDA $16.50
- AVG Volume (30 Days)
- PAMT 6.4K
- VNDA 551.1K
- Earning Date
- PAMT 10-28-2025
- VNDA 10-29-2025
- Dividend Yield
- PAMT N/A
- VNDA N/A
- EPS Growth
- PAMT N/A
- VNDA N/A
- EPS
- PAMT N/A
- VNDA N/A
- Revenue
- PAMT $623,270,000.00
- VNDA $203,467,000.00
- Revenue This Year
- PAMT N/A
- VNDA $15.45
- Revenue Next Year
- PAMT $12.19
- VNDA $37.82
- P/E Ratio
- PAMT N/A
- VNDA N/A
- Revenue Growth
- PAMT N/A
- VNDA 11.78
- 52 Week Low
- PAMT $10.51
- VNDA $3.81
- 52 Week High
- PAMT $23.70
- VNDA $5.70
- Technical
- Relative Strength Index (RSI)
- PAMT 40.19
- VNDA 66.36
- Support Level
- PAMT $10.70
- VNDA $5.46
- Resistance Level
- PAMT $11.55
- VNDA $5.70
- Average True Range (ATR)
- PAMT 0.35
- VNDA 0.18
- MACD
- PAMT 0.02
- VNDA 0.01
- Stochastic Oscillator
- PAMT 28.57
- VNDA 81.36
About PAMT PAMT CORP Common Stock
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.